BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 26369382)

  • 1. Elevated second-trimester maternal serum β-human chorionic gonadotropin and amniotic fluid alpha-fetoprotein as indicators of adverse obstetric outcomes in fetal Turner syndrome.
    Alvarez-Nava F; Soto M; Lanes R; Pons H; Morales-Machin A; Bracho A
    J Obstet Gynaecol Res; 2015 Dec; 41(12):1891-8. PubMed ID: 26369382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [AFP, uE3, beta-hCG levels applied for prenatal diagnosis of Down's syndrome].
    Liao S; Wang Y; Ye G
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):655-8. PubMed ID: 9639764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of second-trimester maternal serum free-beta-human chorionic gonadotropin and alpha-fetoprotein between normal singleton and twin pregnancies: a population-based study.
    Zheng MM; Hu YL; Zhang CY; Ru T; Liu QL; Xu BY; Chen QG; Xu ZF; Zhang Y; Zhong XL
    Chin Med J (Engl); 2010 Mar; 123(5):555-8. PubMed ID: 20367980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A risk prediction model for fetal hypospadias by testing maternal serum AFP and free beta-HCG.
    Chen Y; Huang J; Mei J
    Clin Biochem; 2019 Jul; 69():21-25. PubMed ID: 31152694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down syndrome screening in an Asian population using alpha-fetoprotein and free beta-hCG: a report of the Taiwan Down Syndrome Screening Group.
    Hsu JJ; Hsieh TT; Hsieh FJ
    Obstet Gynecol; 1996 Jun; 87(6):943-7. PubMed ID: 8649703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies.
    Laundon CH; Spencer K; Macri JN; Anderson RW; Buchanan PD
    Prenat Diagn; 1996 Sep; 16(9):853-6. PubMed ID: 8905900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of maternal first and second trimester serum data of β-hCG, PAPP-A, AFP and uE3 in the prediction of preeclampsia].
    Gu W; Lin J; Hou Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):101-7. PubMed ID: 25877605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome.
    Yaron Y; Cherry M; Kramer RL; O'Brien JE; Hallak M; Johnson MP; Evans MI
    Am J Obstet Gynecol; 1999 Oct; 181(4):968-74. PubMed ID: 10521763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops.
    Lambert-Messerlian GM; Saller DN; Tumber MB; French CA; Peterson CJ; Canick JA
    Prenat Diagn; 1998 Oct; 18(10):1061-7. PubMed ID: 9826898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome.
    Spencer K
    Prenat Diagn; 2000 Aug; 20(8):652-6. PubMed ID: 10951476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple marker screening test: identification of fetal cystic hygroma, hydrops, and sex chromosome aneuploidy.
    Wenstrom KD; Boots LR; Cosper PC
    J Matern Fetal Med; 1996; 5(1):31-5. PubMed ID: 8796763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining fetal nuchal fold thickness with second-trimester biochemistry to screen for trisomy 21.
    Borrell A; Mercade I; Casals E; Borobio V; Seres A; Soler A; Fortuny A; Cuckle H
    Ultrasound Obstet Gynecol; 2007 Dec; 30(7):941-5. PubMed ID: 18000942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome.
    Saller DN; Canick JA; Schwartz S; Blitzer MG
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 1):1021-4. PubMed ID: 1384332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human chorionic gonadotrophin and alpha-fetoprotein levels in matched samples of amniotic fluid, extraembryonic coelomic fluid, and maternal serum in the first trimester of pregnancy.
    Wathen NC; Cass PL; Kitau MJ; Chard T
    Prenat Diagn; 1991 Mar; 11(3):145-51. PubMed ID: 1710066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-trimester maternal serum screening for fetal Down syndrome: As a screening test for hemoglobin Bart's disease: A prospective population-based study.
    Wanapirak C; Piyamomgkol W; Sirichotiyakul S; Tongprasert F; Srisupundit K; Luewan S; Traisrisilp K; Jatavan P; Tongsong T
    Prenat Diagn; 2018 Aug; 38(9):700-705. PubMed ID: 29927491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21.
    Souter VL; Nyberg DA; El-Bastawissi A; Zebelman A; Luthhardt F; Luthy DA
    Prenat Diagn; 2002 Mar; 22(3):175-82. PubMed ID: 11920888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population.
    Hsieh TT; Hung TH; Hsu JJ; Shau WY; Su CW; Hsieh FJ
    Obstet Gynecol; 1997 Jun; 89(6):937-40. PubMed ID: 9170469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Second trimester maternal serum screening for Down's syndrome in women of advanced maternal age: a multi-center prospective study].
    Qi QW; Jiang YL; Liu JT; Bian XM; Li Y; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Cai Y
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):737-41. PubMed ID: 19087538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second trimester prenatal screening for Down's syndrome in Mainland Chinese subjects using double-marker analysis of α-fetoprotein and β-human chorionic gonadotropin combined with measurement of nuchal fold thickness.
    Liu F; Liang H; Jiang X; Zhang Y; Xue L; Yang C; Cheng J; Liu P; Liu Y; Guo X
    Ann Acad Med Singap; 2011 Jul; 40(7):315-8. PubMed ID: 21870022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prenatal maternal blood screening for the detection of fetal chromosomal abnormalities: clinical importance of the rate of false positives].
    Alvarez-Nava F; Soto M; Padrón T; Morales A; Villalobos D; Rojas de Atencio A; Prieto M; Martínez MC
    Invest Clin; 2003 Sep; 44(3):195-207. PubMed ID: 14552058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.